Complementary morpholino oligonucleotide to MORF1 (cMORF1) (cMORF1)

The complementary morpholino oligonucleotide to MORF1 (cMORF1) is a synthetic, non-natural nucleic acid analog utilized as a high-affinity probe in pre-targeted nuclear medicine (Liu et al., 2002). It is a member of the phosphorodiamidate morpholino oligomer (PMO) family, which features a backbone of morpholine rings and phosphorodiamidate linkages that are resistant to enzymatic degradation by nucleases (Hnatowich et al., 1996). In a pre-targeting protocol, a primary targeting agent, such as a monoclonal antibody conjugated to the MORF1 sequence, is first administered to bind to a specific disease-associated antigen. Once the primary agent has cleared from the blood, a radiolabeled cMORF1 is injected, which rapidly and specifically hybridizes with the MORF1 sequence at the target site via Watson-Crick base pairing (He et al., 2005). This approach allows for high-contrast imaging and potent radioimmunotherapy by decoupling the slow localization of antibodies from the rapid delivery of the effector molecule, thereby minimizing systemic radiation exposure.

Other names

cMORFComplementary phosphorodiamidate morpholino oligomercMORF1

High-affinity hybridization via Watson-Crick base pairing with a complementary MORF1 sequence conjugated to a primary targeting agent.